Sinopharm Group Co (X2S) Stock Price & Analysis
X2S Stock Chart & Stats
- Day’s Range
- EUR 1.88 - EUR 1.92
- 52-Week Range
- EUR 1.64 - EUR 2.37
- Previous Close
- EUR 1.88
- Volume
- N/A
- Average Volume (3M)
- 1,295
- Market Cap
- EUR 5.92B
- Enterprise Value
- EUR 183.65B
- Total Cash (Recent Filing)
- EUR 41.88B
- Total Debt (Recent Filing)
- EUR 81.32B
- Price to Earnings (P/E)
- 6.3
- Beta
- 0.28
- Next Earnings
- Mar 19, 2027 (Est.)
- EPS Estimate
- 0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 4.08%
Bulls Say, Bears Say
Bulls Say
Distribution Scale
The company’s nationwide distribution footprint, purchasing scale, and coverage of hospitals, clinics, pharmacies, and other providers support a broad operating platform. These capabilities can reinforce customer reach and logistics efficiency, providing a durable foundation for recurring healthcare-product distribution activity.
Cash Generation
Positive operating and free cash flow, together with reasonably strong conversion of net income into free cash flow, indicates that reported earnings have continued to translate into internal funding. This supports ongoing operations, working-capital needs, dividends, and investment without relying entirely on external financing.
Profitable Operating Base
Despite recent pressure, the company has maintained positive profitability and positive historical returns on equity while growing its equity base. That indicates an established operating model capable of producing shareholder returns over time, rather than depending on a temporary period of reported gains.
Bears Say
Revenue Contraction
The recent reversal from earlier revenue growth to contraction signals weaker top-line momentum across the company’s distribution activities. If sustained, slower sales growth can limit operating leverage, reduce the scope for earnings expansion, and make future performance more dependent on efficiency improvements.
Thin And Declining Margins
Very thin net margins leave limited protection against cost pressure or weaker product mix, while the recent compression in gross and operating margins indicates reduced profitability through the business. This constrains earnings resilience and makes modest changes in revenue or expenses more consequential.
Higher Leverage And Weaker FCF
Rising leverage alongside a sharp decline in free cash flow reduces financial flexibility in an already low-margin business. Greater borrowing dependence can increase the importance of maintaining cash generation and restrict the company’s ability to fund growth, dividends, or other priorities during weaker conditions.
Sinopharm Group Co News
X2S FAQ
What was Sinopharm Group Co’s price range in the past 12 months?
What is Sinopharm Group Co’s market cap?
When is Sinopharm Group Co’s upcoming earnings report date?
How were Sinopharm Group Co’s earnings last quarter?
Is Sinopharm Group Co overvalued?
Does Sinopharm Group Co pay dividends?
What is Sinopharm Group Co’s EPS estimate?
How many shares outstanding does Sinopharm Group Co have?
What happened to Sinopharm Group Co’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sinopharm Group Co?
What is the TipRanks Smart Score and how is it calculated?
Sinopharm Group Co Stock Smart Score
Company Description
Sinopharm Group Co
Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are organized across four main divisions. Its Pharmaceutical Distribution segment supplies pharmaceutical goods to a wide range of clients, including hospitals, fellow distributors, retail pharmacies, and clinics. This division additionally offers extensive distribution, logistics, and value-added support to both domestic and international manufacturers and suppliers in the pharmaceutical and healthcare sectors. The Medical Devices segment is solely focused on the distribution of various medical equipment. The "Other Business" segment is involved in the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core areas, the company also engages in property rental and management. It further distributes specialized items such as medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products. Sinopharm provides a comprehensive array of services, including IT development, medicine and health consultations, investment services, import/export facilitation for goods and technology, various business and market information consulting, and the organization of conventions and exhibitions. Moreover, it oversees medical project investments, offers related consulting, and provides technological training. Notably, Sinopharm Group has established a strategic alliance with I-Mab to enhance its commercial capabilities and accelerate its market entry strategies. Founded in Shanghai, China, in 2003, Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Wanyong Lian
- Employees
- 94,910
- Website
- www.sinopharmgroup.com.cn
- Address
- Sinopharm Group Building, Shanghai, SH, 200023, CN
Sinopharm Group Co (X2S) Earnings & Revenues
X2S Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 2 | 4 |
| Technical Analysis | 3 | 2 | 4 |
| Moving Averages | 12 | 0 | 0 |
